Sulfacetamide

Summary

Sulfacetamide (CHEMBL455) is an approved small-molecule antimicrobial agent (ATC S01AB04); indicated across 5 conditions including acne and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AB04 (+1 more)
• Indications: 5 conditions
• Chemistry: 214.24 Da · C8H10N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL455
Name	Sulfacetamide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5320
ChEBI	CHEBI:63845
ATC	S01AB04, D10AF06
Molecular formula	C8H10N2O3S
Molecular weight	214.24
InChIKey	SKIVFJLNDNKQPD-UHFFFAOYSA-N

SMILES: CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N

IUPAC name: N-(4-aminophenyl)sulfonylacetamide

ChEBI definition: A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.

Pharmacological roles (ChEBI): antimicrobial agent, antiinfective agent, EC 2.5.1.15 (dihydropteroate synthase) inhibitor, antibacterial drug.

Also known as: Fml-s, NSC-63871, Sulfacetamida, Sulfacetamide, Sulfacetamide (triple sulfa), Sulfacetamide component of gyne-sulf, Sulfacetamide component of sultrin, Sulfacetamide component of trysul, Sulfacetamide component of vagilia, Sulfacetamidum, Sulster, Triple sulfa (sulfacetamide)

Parent form; salt/anhydrous children: CHEMBL1200416, CHEMBL1723241

Patent coverage: 5,230 distinct patent families (18,129 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Dihydrofolate reductase, Tyrosyl-DNA phosphodiesterase 1, Survival motor neuron protein, Thyrotropin receptor, Dihydrofolate reductase.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TSHR	6.2	Potency	631	nM	CHEMBL_ACT_3915163
TSHR	6.2	Potency	631	nM	CHEMBL_ACT_4699088
SMN1	5.95	Potency	1122	nM	CHEMBL_ACT_3885189
TDP1	5.05	Potency	8912	nM	CHEMBL_ACT_3930705

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acne	4	MONDO:0011438	EFO:0003894
eye infectious disorder	4	MONDO:0043885	EFO:1001888
conjunctivitis	4	MONDO:0003799	EFO:0009450
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazid	CPIC	G6PD

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).